TY  - GEN
AU  - Kardos, Peter
AU  - Worsley, Sally
AU  - Singh, Dave
AU  - Roman-Rodriguez, Miguel
AU  - Newby, David E
AU  - Mullerova, Hana
PY  - 2016
DO  - 10.2147/COPD.S118867
SN  - 1178-2005
UR  - http://hdl.handle.net/20.500.12105/20235
AB  - Long-acting muscarinic antagonist (LAMA) or long-acting beta2-agonist (LABA) bronchodilators and their combination are recommended for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Although the efficacy of LAMAs and LABAs...
LA  - eng
KW  - Cardiovascular
KW  - Cerebrovascular
KW  - Real-world observational study
KW  - Safety
KW  - Umeclidinium
KW  - Vilanterol
KW  - Cardiovascular Diseases
KW  - Randomized Controlled Trials as Topic
KW  - Chlorobenzenes
KW  - Drug Combinations
KW  - Risk Assessment
KW  - Pulmonary Disease, Chronic Obstructive
KW  - Humans
KW  - Benzyl Alcohols
KW  - Bronchodilator Agents
KW  - Patient Safety
KW  - Lung
KW  - Research Design
KW  - Prospective Studies
KW  - Time Factors
KW  - Muscarinic Antagonists
KW  - Quinuclidines
KW  - Risk Factors
KW  - Evidence-Based Medicine
KW  - Patient Selection
KW  - Comorbidity
TI  - Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD
TY  - research article
ER  -